Proactive Investors - Run By Investors For Investors

Silence Therapeutics to be a clinical-stage company by year-end

Torsten Hoffmann, chief operating officer at Silence Therapeutics PLC (LON:SLN) chats to Proactive's Andrew Scott following the release of their preliminary 2017 results.

Hoffmann says the big focus for them is working towards filing their first GalNAc-siRNA CTA (clinical trial authorisation) for the treatment of liver-related iron overload disorders by the end of 2018.

Five senior managers have recently been recruited to spearhead the clinical drive.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full SLN profile View Profile

Silence Therapeutics plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use